Compare Ascendis Pharma A/S (ASND) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Hilton Hotels Corporation Common Stock — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Hilton Hotels Corporation Common Stock trades at $316.39 (market cap $70.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 4.2× Ascendis Pharma A/S's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HLT | |
|---|---|---|
Market Cap | $16.67B | $70.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $350.22 |
52-Week Low | $189.74 | $256.75 |
Enterprise Value | $17.04B | $83.83B |
Dividend Yield | — | 0.19% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
